Infección orofacial por Conidiobolus coronatus reporte de caso

Abstract

Entomophtoramycosis is a type of subcutaneous mycosis which includes both basidiobolomycosis and conidiobolomycosis; the latter is caused by Conidiobolus coronatus, a saprophytic fungus which lives in tropical soils. This mycosis characteristically affects the paranasal sinuses and oropharynx, with the potential to deform the face in patients without apparent immunodeficiency. It has a chronic course of infection with a tendency to form granulomas visible using histology. We present the case of a 28 year-old male agricultural worker, with a clinical profile of 6 months' evolution of rhinofacial tumefaction, nasal obstruction and post-nasal drip who was diagnosed with conidiobolomycosis by means of tissue culture after multiple biopsies of the facial area. The patient received antifungal treatment with amphotericin B and subsequently with itraconazol, resulting in a dramatic improvement without the need for surgical treatment; itraconazol was administered for one year and there was no evidence of relapse at the end of this period. Due to the low frequency of this disease there is no established treatment strategy; however, the use of azoles such as itraconazol with or without adjuvant surgical treatment is increasingly seen in case reports. The present report adds to the clinical experience in Colombia of this rare mycosis and also describes the long-term clinical and therapeutic response.

A Rhinofacial Conidiobolus coronatus Fungal Infection Presenting as an Intranasal Tumour

“…As in the current case, most published reports of rhinofacial C. coronatus infections have occurred in males with normal immune status who have recently travelled to a tropical region. 5,[9][10][11] Overall, very few cases of rhinofacial C. coronatus infections have been reported in the literature; as such, early identification of the organism remains challenging. 1,3,4 To the best of the authors' knowledge, the current case is the first report of a patient with rhinofacial conidiobolomycosis from the UAE.…”

Validación de la metodología para cuantificar el fluconazol y sus impurezas orgánicas en materia prima por cromatografía líquida de alta resolución

“…Es un ingrediente farmacéutico activo, un antifúngico clasificado en el grupo de los azoles, más específicamente, como un triazol (2). Se administra para tratar infecciones producidas por hongos (3,4) Es ampliamente usado para tratar casos de infecciones como la candidiasis de las mucosas e infecciones sistémicas, incluidas la candidiasis, la coccidioidomicosis y la criptococosis (5,6). Actúa inhibiendo la desmetilación del citocromo P-450 fúngico (C-14-α-desmetilasa), lo que resulta en la acumulación de 14-α-metil-esteroles fúngicos, la pérdida de los esteroles fúngicos normales y la actividad fungistática.…”